Our website uses cookies. We use cookies to remember settings and to help provide you with the best experience we can. We also use cookies to continuously improve our website by compiling visitor statistics. Read more about cookies

Josef Vormoor

Clinical Co-Investigator and Clinical Director of Haemato-oncology
Josef is pediatric oncologist in the Princess Máxima Center and closely co-principal investigator in the group of Olaf Heidenreich.
Phone +31 (0) 6 50 17 30 51

Josef Vormoor received his research MD from Münster University for his work on childhood AML. He gained further research experience as a postdoc in John Dick’s lab at the Hospital for Sick Children in Toronto, working on normal and leukemic hematopoietic stem cells. He then established his own research group on childhood ALL at the University Children’s Hospital in Münster. In 2006, he moved to Newcastle, first as Professor of Clinical Pediatric Oncology, from 2007 as Sir James Spence Professor of Child Health and since 2013 as Director of the Northern Institute for Childhood Cancer. His research covers mechanism of leukemic stemness, communication of the leukemic cells with their microenvironment and preclinical and early clinical drug development for childhood leukemia. 

  • Implementation of paediatric precision oncology into clinical practice

    • nov. 2022
    • Karin P.S., Langenberg, et al
    • European Journal of Cancer
  • Epigenetic regulator genes direct lineage switching in MLL/AF4 leukemia

    • okt. 2022
    • Ricky, Tirtakusuma, et al
    • Blood
  • hiPSC-derived bone marrow milieu identifies a clinically actionable driver of niche-mediated treatment resistance in leukemia

    • aug. 2022
    • Deepali, Pal, et al
    • Cell Reports Medicine
  • Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia

    • apr. 2022
    • Linde, Dekker, et al
    • Blood advances
  • Selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex)

    • mrt. 2022
    • Tobias, Menne, et al
    • BMJ Open
View all publications